$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

$halo Overview Financials Valuation SEC Filings Company Website

2016 Q2 Form 10-Q Financial Statement

#000115903616000125 Filed on August 09, 2016

Income Statement

Concept	2016 Q2	2015 Q2
Revenue	$33.34M	$33.34M
YoY Change	0.0%	81.32%
Cost Of Revenue	$8.308M	$8.144M
YoY Change	2.01%	37.47%
Gross Profit	$5.391M	$5.391M
YoY Change	0.0%	51.01%
Gross Profit Margin	16.17%	16.17%
Selling, General & Admin	$11.22M	$9.814M
YoY Change	14.34%	12.13%
% of Gross Profit	208.14%	182.04%
Research & Development	$35.53M	$21.20M
YoY Change	67.63%	13.65%
% of Gross Profit	659.06%	393.16%
Depreciation & Amortization	$600.0K	$400.0K
YoY Change	50.0%	0.0%
% of Gross Profit	11.13%	7.42%
Operating Expenses	$55.06M	$31.01M
YoY Change	77.56%	13.17%
Operating Profit	-$21.72M	$4.231M
YoY Change	-613.42%	-128.32%
Interest Expense	$5.249M	$1.299M
YoY Change	304.08%	-10.48%
% of Operating Profit		30.7%
Other Income/Expense, Net	$397.0K	$87.00K
YoY Change	356.32%	-26.27%
Pretax Income	-$26.58M	$3.019M
YoY Change	-980.26%	-118.52%
Income Tax	$300.0K	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$26.88M	-$26.88M
YoY Change	0.0%	65.15%
Net Earnings / Revenue	-80.62%	-80.62%
Basic Earnings Per Share	-$0.21	$0.02
Diluted Earnings Per Share	$0.02	$0.02
COMMON SHARES
Basic Shares Outstanding	128.0M shares	126.1M shares
Diluted Shares Outstanding	134.5M shares	134.5M shares

Balance Sheet

Concept	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$230.0M	$140.7M
YoY Change	63.47%	-4.67%
Cash & Equivalents	$61.23M	$67.77M
Short-Term Investments	$168.8M	$72.90M
Other Short-Term Assets	$20.40M	$10.30M
YoY Change	98.06%	28.75%
Inventory	$10.76M	$7.723M
Prepaid Expenses	$16.74M
Receivables	$23.23M	$9.738M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$284.3M	$168.4M
YoY Change	68.81%	-4.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.682M	$2.594M
YoY Change	80.49%	-22.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$7.100M	$3.000M
YoY Change	136.67%	-3.23%
Total Long-Term Assets	$11.78M	$5.605M
YoY Change	110.22%	-12.82%
TOTAL ASSETS
Total Short-Term Assets	$284.3M	$168.4M
Total Long-Term Assets	$11.78M	$5.605M
Total Assets	$296.1M	$174.0M
YoY Change	70.14%	-4.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.650M	$4.138M
YoY Change	-11.79%	5.83%
Accrued Expenses	$23.85M	$14.82M
YoY Change	60.93%	-9.93%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.288M	$9.656M
YoY Change	-65.95%	55.67%
Total Short-Term Liabilities	$38.89M	$35.04M
YoY Change	10.98%	10.46%
LONG-TERM LIABILITIES
Long-Term Debt	$204.9M	$40.10M
YoY Change	410.97%	-8.03%
Other Long-Term Liabilities	$600.0K	$3.429M
YoY Change	-82.5%	20.15%
Total Long-Term Liabilities	$600.0K	$3.429M
YoY Change	-82.5%	20.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$38.89M	$35.04M
Total Long-Term Liabilities	$600.0K	$3.429M
Total Liabilities	$39.49M	$38.47M
YoY Change	2.64%	11.26%
SHAREHOLDERS EQUITY
Retained Earnings	-$529.0M	-$462.5M
YoY Change	14.38%	8.86%
Common Stock	$538.7M	$512.8M
YoY Change	5.06%	6.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.920M	$50.23M
YoY Change
Total Liabilities & Shareholders Equity	$296.1M	$174.0M
YoY Change	70.14%	-4.4%

Cashflow Statement

Concept	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	-$26.88M	-$26.88M
YoY Change	0.0%	65.15%
Depreciation, Depletion And Amortization	$600.0K	$400.0K
YoY Change	50.0%	0.0%
Cash From Operating Activities	-$12.90M	$8.900M
YoY Change	-244.94%	-156.33%
INVESTING ACTIVITIES
Capital Expenditures	-$1.200M	-$300.0K
YoY Change	300.0%	-25.0%
Acquisitions
YoY Change
Other Investing Activities	$700.0K	$11.00M
YoY Change	-93.64%	-300.0%
Cash From Investing Activities	-$500.0K	$10.80M
YoY Change	-104.63%	-283.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.500M	3.700M
YoY Change	48.65%	208.33%
NET CHANGE
Cash From Operating Activities	-12.90M	8.900M
Cash From Investing Activities	-500.0K	10.80M
Cash From Financing Activities	5.500M	3.700M
Net Change In Cash	-7.900M	23.40M
YoY Change	-133.76%	-214.15%
FREE CASH FLOW
Cash From Operating Activities	-$12.90M	$8.900M
Capital Expenditures	-$1.200M	-$300.0K
Free Cash Flow	-$11.70M	$9.200M
YoY Change	-227.17%	-159.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	589000	USD
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001159036
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	129414080	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	HALOZYME THERAPEUTICS INC.
	dei	Trading Symbol TradingSymbol	HALO
CY2015Q4	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	25939000	USD
CY2016Q2	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	5001000	USD
CY2015Q4	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	2442000	USD
CY2016Q2	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	2467000	USD
CY2015Q4	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	4996000	USD
CY2016Q2	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	16575000	USD
CY2015Q4	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	8617000	USD
CY2016Q2	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	10995000	USD
CY2015Q4	halo	Accrued Outsourced Researchand Development Expenses Long Term AccruedOutsourcedResearchandDevelopmentExpensesLongTerm	784000	USD
CY2016Q2	halo	Accrued Outsourced Researchand Development Expenses Long Term AccruedOutsourcedResearchandDevelopmentExpensesLongTerm	30000	USD
CY2015Q4	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	6205000	USD
CY2016Q2	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	3120000	USD
CY2016Q2	halo	Additional Maximum Proceeds Receivablefrom Collaboratorof Licenseand Collaborative Agreement Upon Achievementof Clinical Development Milestones AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones	62500000	USD
CY2016Q2	halo	Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets	12000000	USD
CY2015Q4	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	967000	USD
CY2016Q2	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	816000	USD
CY2015Q4	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	9225000	USD
CY2016Q2	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	8044000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4499000	USD
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3650000	USD
CY2015Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	33377000	USD
CY2016Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	24043000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	32410000	USD
CY2016Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23227000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-548000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-397000	USD
CY2015Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	27576000	USD
CY2016Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	23881000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	26792000	USD
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23851000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10318000	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10894000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-99000	USD
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	216000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	525628000	USD
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	538585000	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5905000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10035000	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6371000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1317000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1266000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-131000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12188000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	528000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1843000	USD
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	400000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9200000	shares
CY2016Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13200000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13200000	shares
CY2015Q4	us-gaap	Assets Assets	181789000	USD
CY2016Q2	us-gaap	Assets Assets	296127000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	171772000	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	284344000	USD
CY2015Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	103642000	USD
CY2016Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	210540000	USD
CY2015Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	221000	USD
CY2015Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	99000	USD
CY2016Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	65047000	USD
CY2016Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	168757000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	65146000	USD
CY2016Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	168541000	USD
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	65047000	USD
CY2016Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	168757000	USD
CY2016Q2	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	144700000	USD
CY2016Q2	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	6
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61389000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67769000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43292000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61233000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6380000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	17941000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	128152000	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	129411000	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	128152000	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	129411000	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	128000	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	129000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3006000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-167000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1436000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-120000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12088000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26747000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46376000	USD
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	8144000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	14638000	USD
CY2016Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	8308000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	16070000	USD
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	39153000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	71730000	USD
CY2016Q2	us-gaap	Costs And Expenses CostsAndExpenses	55059000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	113727000	USD
CY2016Q2	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	300000	USD
CY2015Q4	us-gaap	Deferred Revenue DeferredRevenue	53223000	USD
CY2016Q2	us-gaap	Deferred Revenue DeferredRevenue	49968000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9304000	USD
CY2016Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8096000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	43919000	USD
CY2016Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	41872000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	400000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	800000	USD
CY2016Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	600000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	816000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1112000	USD
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8636000	USD
CY2016Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5993000	USD
CY2015Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2016Q2	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3019000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12089000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26575000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-46391000	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	300000	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	300000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	300000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4811000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	300000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1691000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9183000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2957000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3254000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	1299000	USD
	us-gaap	Interest Expense InterestExpense	2598000	USD
CY2016Q2	us-gaap	Interest Expense InterestExpense	5249000	USD
	us-gaap	Interest Expense InterestExpense	9125000	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	331000	USD
CY2016Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	641000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	9489000	USD
CY2016Q2	us-gaap	Inventory Net InventoryNet	10755000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	677000	USD
CY2016Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1335000	USD
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8481000	USD
CY2016Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8779000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	181789000	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	296127000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	62457000	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	38885000	USD
CY2015Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	24660000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	26691000	USD
CY2016Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	7365000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	25537000	USD
CY2015Q4	us-gaap	Long Term Debt LongTermDebt	27971000	USD
CY2016Q2	us-gaap	Long Term Debt LongTermDebt	204850000	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	21862000	USD
CY2016Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	3288000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	10930000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	149866000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	351000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-106057000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4901000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-25868000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	3019000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12089000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-26875000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-46691000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	4231000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9680000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-21723000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-37892000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4118000	USD
CY2016Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3773000	USD
CY2015Q4	us-gaap	Other Assets OtherAssets	530000	USD
CY2016Q2	us-gaap	Other Assets OtherAssets	669000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-13000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	128000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	315000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4443000	USD
CY2016Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	600000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	87000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	189000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	397000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	626000	USD
CY2015Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1198000	USD
CY2016Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1520000	USD
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	5478000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	33184000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	138399000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	390000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2266000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	10953000	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	10233000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5379000	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3632000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	5574000	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	6601000	USD
CY2015Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	16155000	USD
CY2016Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	16740000	USD
CY2016Q2	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	0	USD
	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	0	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	203005000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	10930000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1111000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	33925000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	34608000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14261000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15576000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3943000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4682000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	54250000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21195000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37879000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35530000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	75630000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-482658000	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-529010000	USD
CY2015Q2	us-gaap	Revenues Revenues	43384000	USD
	us-gaap	Revenues Revenues	62050000	USD
CY2016Q2	us-gaap	Revenues Revenues	33336000	USD
	us-gaap	Revenues Revenues	75835000	USD
CY2015Q2	us-gaap	Royalty Revenue RoyaltyRevenue	6382000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	13157000	USD
CY2016Q2	us-gaap	Royalty Revenue RoyaltyRevenue	12272000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	23659000	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	12342000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	22202000	USD
CY2016Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	13699000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	26639000	USD
CY2015Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9814000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19213000	USD
CY2016Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11221000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	22027000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10035000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	12188000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0191
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0191
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0139
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0173
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0149
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0134
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0124
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0124
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	900000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2500000	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	700000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3500000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9000000	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11800000	shares
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y5M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y5M
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	42999000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	9920000	USD
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	134507000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	125723000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	127958000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	127787000	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	126144000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	125723000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	127958000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	127787000	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies. We are seeking to translate our unique knowledge of the tumor microenvironment to create therapies that have the potential to improve cancer patient survival. Our research primarily focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary enzymes are used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for potential clinical benefit. We exploit our technology and expertise using a two pillar strategy that we believe enables us to manage risk and cost by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products that combine our technology with the collaborators’ proprietary compounds.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is the active ingredient in our first commercially approved product, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> recombinant, and it works by temporarily breaking down hyaluronan (or “HA”), a naturally occurring complex carbohydrate that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We believe this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as our ENHANZE</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">™</sup></font><font style="font-family:inherit;font-size:10pt;"> Technology. We license the ENHANZE Technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the subcutaneous route of administration.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have ENHANZE collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (“Roche”), Baxalta US Inc. and Baxalta GmbH (Baxalta Incorporated was acquired by Shire plc in June 2016) (“Baxalta”), Pfizer Inc. (“Pfizer”), Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), and Eli Lilly and Company (“Lilly”). We receive royalties from two of these collaborations, including royalties from sales of one product approved in both the United States and outside the United States from the Baxalta collaboration and from sales of two products approved for marketing outside the United States from the Roche collaboration. Future potential revenues from the sales and/or royalties of our approved products, product candidates, and ENHANZE collaborations will depend on the ability of Halozyme and our collaborators to develop, manufacture, secure and maintain regulatory approvals for approved products and product candidates and commercialize product candidates.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary development pipeline consists primarily of clinical stage product candidates in oncology. Our lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a molecular entity we are developing in combination with currently approved cancer therapies as a candidate for the systemic treatment of tumors that accumulate HA. We have demonstrated that when HA accumulates in a tumor, it can cause higher pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. PEGPH20 has been demonstrated in animal models to work by temporarily degrading HA surrounding cancer cells resulting in reduced pressure and increased blood flow to the tumor thereby enabling increased amounts of anticancer treatments administered concomitantly gaining access to the tumor. We are currently in Phase 2 and Phase 3 clinical testing for PEGPH20 with gemcitabine and nab-paclitaxel (ABRAXANE</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">) in stage IV pancreatic ductal adenocarcinoma (“PDA”) (Studies 109-202 and 109-301), in Phase 1b clinical testing </font><font style="font-family:inherit;font-size:11pt;">for </font><font style="font-family:inherit;font-size:10pt;">PEGPH20 with docetaxel (Taxotere</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">) in non-small cell lung cancer (Study 107-201), in Phase 1b clinical testing for</font><font style="font-family:inherit;font-size:11pt;"> </font><font style="font-family:inherit;font-size:10pt;">PEGPH20 with KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> in non-small cell lung cancer and gastric cancer (Study 107-101) and in Phase 1b/2 clinical testing for PEGPH20 with eribulin (HALAVEN</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">) in first line and second line HER2-negative high-HA metastatic breast cancer.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these notes to condensed consolidated financial statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.’s wholly owned subsidiaries, Halozyme Holdings Ltd. and Halozyme Royalty LLC.</font></div></div>

Files In Submission

Name	View Source	Status
0001159036-16-000125-index-headers.html	Edgar Link	pending
0001159036-16-000125-index.html	Edgar Link	pending
0001159036-16-000125.txt	Edgar Link	pending
0001159036-16-000125-xbrl.zip	Edgar Link	pending
ex102loanandsecurityagreem.htm	Edgar Link	pending
ex311q22016.htm	Edgar Link	pending
ex312q22016.htm	Edgar Link	pending
ex32q22016.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
halo-20160630.xml	Edgar Link	completed
halo-20160630.xsd	Edgar Link	pending
halo-20160630_cal.xml	Edgar Link	unprocessable
halo-20160630_def.xml	Edgar Link	unprocessable
halo-20160630_lab.xml	Edgar Link	unprocessable
halo-20160630_pre.xml	Edgar Link	unprocessable
halo2q2016-10q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
slide1a08.jpg	Edgar Link	pending
slide2a08.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

2016 Q2 Form 10-Q Financial Statement

#000115903616000125 Filed on August 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO HALOZYME THERAPEUTICS, INC. Stock $halo

2016 Q2 Form 10-Q Financial Statement

#000115903616000125 Filed on August 09, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo